New Stocks And Investor Ideas In Entertainment, Mining And Biotech (CSE: GMNG) (CSE: PEK) (Nasdaqgm: THRD)


(MENAFN- Investor Ideas)

, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Entertainment, Mining and Biotech. Today's stocks have been added to our lists of free stock directories in each sector.

The newest entertainment company provides short and long-form video content and broadcast distribution across its owned & operated channels.

The latest mining company operates in Canada while the newest biotech company is a recent Nasdaq IPO focused on allergy and inflammation treatments.

New Stocks added to the :

( , GMNG.WT) is a media & entertainment company providing citrates short and long -form video content, with broadcast distribution across its owned & operated channels. Generating over 1.7 billion monthly video views across its 27 owned and operated channels, Gamelancer has over 32,000,000 followers on TikTok, Instagram, and Snapchat, predominantly located in the US, Canada, the UK, and Australia. Gamelancer sells creative content campaigns broadcast across network for the world's largest brands. With advanced user data analytics, we provide our audience curated content relevant to the GenZ & Millennial gaming community, which allows brands unparalleled access to the largest media inventory in gaming on TikTok. Gamelancer also monetizes across its variety of Snapchat Discover channels with monthly recurring revenue in partnership with Snapchat.

New Stocks added to the :

Peak Minerals Ltd. ( ) is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration on the Aida Project. The Aida Property consists of five non-surveyed contiguous mineral claims totaling 2,335.42 hectares located within Kamloops Mining Division of British Columbia.

New Stocks added to the :

. ( ) is a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation. The company's lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. THB001 is currently being evaluated in a Phase 1b proof-of-concept study in chronic inducible urticaria. With promising drug-like properties and an encouraging early clinical profile, THB001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory and gastrointestinal allergic and mast-cell-mediated inflammatory diseases.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - Big Investing Ideas

We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea's original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast, Cannabis News and Stocks on the Move Podcast, Cleantech and Climate Change Podcast, Exploring Mining Podcast, Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water.

Public companies within the sectors we cover use our news and content to tell their story to interested investors. Paid for content is disclosed.

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: Learn more about publishing your news release and our other news services on the Investorideas.com newswire and tickertagstocknews.com

Global investors must adhere to regulations of each country.

MENAFN07102022000142011025ID1104986664


Investor Ideas

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.